Kidney Disease Prevention: A Practical Guide

Approximately 37 million Americans are living with chronic kidney disease, and a substantial proportion of them developed it from conditions that are preventable, treatable, or significantly delayable — most notably type 2 diabetes and high blood pressure. Kidney disease prevention is not a matter of avoiding a single risk or taking a single medication; it is a multifaceted process of managing the conditions that drive kidney damage, detecting changes early when they are still reversible, and sustaining those efforts across years rather than weeks. This guide is for anyone in a high-risk group who wants to understand what kidney disease prevention actually involves in practice — and for those who have already received an early diagnosis and want to know what they can do to protect their remaining function.

Who Is Most at Risk for Kidney Disease

Kidney disease does not arise equally across all populations. Certain conditions, demographic factors, and medical histories create substantially elevated risk, and identifying which categories apply is the starting point for both prevention and screening decisions.

Type 2 diabetes is the leading cause of kidney failure in the United States, responsible for approximately 38 percent of new ESRD cases annually. Persistent elevated blood glucose damages the small blood vessels of the glomeruli — the filtering units — through multiple mechanisms including advanced glycation end products, oxidative stress, and inflammation, ultimately leading to glomerulosclerosis and progressive eGFR decline. Every person with type 2 diabetes should be screened for kidney disease annually with both an eGFR and a urine albumin-to-creatinine ratio (uACR).

Hypertension is the second leading cause, accounting for approximately 25 percent of new kidney failure cases. Chronically elevated blood pressure causes arteriosclerosis of the small vessels feeding the glomeruli, producing ischemic injury over years. The relationship is bidirectional — kidney disease also worsens hypertension — making early BP control critical before the cycle becomes self-reinforcing.

Family history of kidney disease or kidney failure raises risk through multiple pathways, including inherited single-gene disorders (polycystic kidney disease, Alport syndrome, FSGS with genetic mutations), polygenic risk scores, and shared environmental risk factors within families. Anyone with a first-degree relative who has required dialysis or a kidney transplant should be screened earlier and more consistently than the general recommendation.

Age over 60 confers risk through natural age-related eGFR decline — approximately 0.75 ml/min/year after age 30 — combined with the increased prevalence of diabetes, hypertension, and cardiovascular disease that accumulates with age. Older kidneys have less functional reserve and are less resilient to insults like acute kidney injury, nephrotoxic medications, or dehydration.

Obesity and metabolic syndrome promote kidney disease through glomerulomegaly (enlargement of the glomeruli to manage the metabolic demands of excess body mass), hyperfiltration (the early phase where kidneys work harder to compensate), adipokine-driven inflammation, and the downstream development of type 2 diabetes and hypertension. Body mass index above 35 is associated with a substantially elevated risk of proteinuric kidney disease.

African American ancestry is associated with a 3.7-fold higher risk of end-stage kidney disease compared to white Americans. Much of this disparity is driven by variants in the APOL1 gene — specifically the G1 and G2 risk alleles — which dramatically elevate risk for focal segmental glomerulosclerosis (FSGS) and hypertensive ESRD. Approximately 13 percent of Black Americans carry two APOL1 risk alleles (the high-risk genotype). This genetic predisposition does not render prevention useless — aggressive blood pressure control and early nephrology involvement remain highly effective — but it argues for heightened vigilance in screening and risk factor management.

Prior acute kidney injury (AKI) is an under-recognized CKD risk factor. Even when kidney function appears to recover fully after an AKI episode, research shows that permanent nephron loss occurs, resetting the baseline and accelerating the trajectory toward later-stage disease. Anyone who has had a hospitalization involving AKI — from sepsis, major surgery, severe dehydration, or contrast nephropathy — should ensure their primary care provider is aware and includes CKD monitoring in their ongoing care plan.

Other high-risk groups include individuals with autoimmune diseases (lupus, ANCA vasculitis, IgA nephropathy), those with a history of recurrent urinary tract infections or kidney stones, and anyone with chronic daily NSAID or analgesic use, which causes chronic interstitial nephritis — a form of kidney damage that is common, slowly progressive, and entirely preventable.

The Screening Tests That Catch CKD Early

The most frustrating feature of early chronic kidney disease is that the most effective interventions are available precisely at the stage when patients feel completely normal — and when testing is most likely to be overlooked. Screening in high-risk populations is the mechanism that closes this gap.

Two laboratory measurements form the core of CKD screening: the estimated glomerular filtration rate (eGFR), calculated from serum creatinine, and the urine albumin-to-creatinine ratio (uACR), measured on a first-morning urine sample. The eGFR quantifies kidney function; the uACR detects kidney damage before function declines. A uACR of 30 mg/g or above on two separate measurements taken at least three months apart confirms CKD-level albuminuria even when eGFR remains normal — an important distinction because many patients with early diabetic kidney disease have significant albuminuria before any eGFR drop appears.

The problem in primary care is that eGFR is routinely calculated from standard metabolic panels, but uACR is frequently not ordered. For the highest-risk patients — those with diabetes or hypertension — KDIGO guidelines recommend annual testing of both measurements. The American Diabetes Association recommends uACR testing for all type 2 diabetes patients at the time of diagnosis and then annually thereafter. Despite these guidelines, studies consistently show that uACR is underordered, meaning early kidney damage is missed during the window when treatment is most effective. A detailed explanation of what each kidney test measures and how results are interpreted is available in our guide on how doctors diagnose kidney disease.

Blood Pressure Control — The Foundation of Kidney Protection

Blood pressure management is the single most important modifiable intervention for kidney disease prevention in the general high-risk population. This is true because the two leading causes of kidney failure — diabetic nephropathy and hypertensive nephrosclerosis — are both directly driven by elevated pressure within the glomerular vasculature. Controlling systemic blood pressure protects the kidneys regardless of whether the primary diagnosis is diabetes, hypertension, or both.

The target blood pressure for kidney protection is below 130/80 mmHg — the threshold recommended by both KDIGO 2024 and the 2021 American Heart Association/American College of Cardiology guidelines for patients with CKD or significant CKD risk. For patients who also have proteinuria or diabetes, an ACE inhibitor or ARB is the preferred antihypertensive class: these agents reduce intraglomerular pressure by dilating the efferent arteriole, which directly lowers the pressure-driven protein filtration (proteinuria) and slows glomerular scarring. This kidney-protective effect is distinct from blood pressure lowering by other agents — achieving the same systolic BP with a calcium channel blocker or beta-blocker alone does not provide the same degree of proteinuria reduction or kidney protection.

The DASH (Dietary Approaches to Stop Hypertension) diet reduces systolic blood pressure by 8 to 11 mmHg in clinical trials — comparable to adding a single antihypertensive medication. It emphasizes fruits, vegetables, whole grains, low-fat dairy, and reduced sodium intake to below 2.3 grams per day. Sodium restriction is worth emphasizing separately: dietary sodium above this threshold raises blood pressure and directly elevates intraglomerular pressure, independently worsening kidney stress. Processed foods — soups, deli meats, snack foods, restaurant meals — are the dominant source of dietary sodium for most people, not the salt shaker at the table.

One combination to be aware of: the concurrent use of an NSAID with an ACE inhibitor or ARB and a diuretic — sometimes called the “triple whammy” — creates an acute kidney injury risk through additive effects on renal blood flow that is significantly greater than any of the three alone. Patients on ACE inhibitors or ARBs and diuretics should be explicitly counseled to avoid NSAIDs, including over-the-counter ibuprofen and naproxen.

Blood Sugar Control in Diabetes

For the approximately 40 percent of CKD risk that traces to diabetes, glucose control is one of the most effective prevention tools available. The UKPDS (UK Prospective Diabetes Study) demonstrated a “legacy effect” — patients randomized to intensive glucose control in the trial had significantly lower rates of diabetic complications, including kidney disease, even years after the trial ended and glucose control was no longer differentiated between groups. This establishes that early, sustained HbA1c control — targeting at or below 7 percent — reduces the incidence of diabetic kidney disease in a way that benefits the kidney long-term.

Modern diabetes management for kidney prevention extends beyond HbA1c. SGLT2 inhibitors (empagliflozin, dapagliflozin) have kidney-protective effects independent of glucose lowering, including reduction of intraglomerular hyperfiltration and anti-inflammatory effects. Their benefit in reducing CKD progression in patients with type 2 diabetes and established CKD is robust (CREDENCE, DAPA-CKD, EMPA-KIDNEY trials), and their use in diabetes management before CKD develops serves both glycemic and kidney prevention purposes. GLP-1 receptor agonists — semaglutide, liraglutide, dulaglutide — provide substantial weight loss, blood pressure reduction, and direct kidney-protective effects (FLOW trial data), making them an important tool for patients with diabetes and obesity who are at the highest kidney risk from the combination of hyperglycemia, hyperfiltration, and hypertension.

Protecting Your Kidneys With Diet and Lifestyle

Dietary and lifestyle choices create the metabolic environment in which the kidneys function — and in which kidney disease either develops or is held at bay. Several specific choices have clear, evidence-based effects on kidney risk.

Sodium restriction to below 2.3 grams per day reduces both blood pressure and intraglomerular pressure directly. The reduction in albuminuria seen with dietary sodium restriction is measurable within weeks in patients with diabetes or hypertension — typically in the range of 20 to 30 percent when compliance is maintained. This is not a minor effect; it is comparable to the proteinuria reduction seen with an ACE inhibitor dose adjustment, achieved through diet alone.

Protein moderation is relevant for kidney protection even in non-CKD patients with high risk. Diets providing protein above 1.3 grams per kilogram of body weight per day increase glomerular filtration pressure, promoting hyperfiltration and increasing proteinuria. High-protein diets — including those promoted for athletic performance or weight loss — are not neutral for the kidneys in at-risk populations. A protein intake consistent with normal dietary guidelines (0.8–1.0 g/kg/day) avoids this additional stress without compromising nutritional adequacy.

Weight management through caloric balance, dietary quality, and regular exercise reduces the hyperfiltration-driven kidney stress of obesity. Even a 5 to 10 percent reduction in body weight produces measurable reductions in proteinuria and blood pressure in obese patients — a direct kidney-protective effect alongside the metabolic benefits.

NSAID avoidance is one of the most important yet underappreciated kidney protection steps for the general population. Ibuprofen and naproxen are the most commonly used over-the-counter pain medications in the world. They reduce renal blood flow by blocking prostaglandin-mediated vasodilation of the afferent arteriole — a mechanism that is inconsequential in a healthy person but causes AKI in volume-depleted, diabetic, hypertensive, or CKD patients. Chronic daily NSAID use causes chronic interstitial nephritis — irreversible kidney scarring — over years of use. Acetaminophen at recommended doses is the safe alternative for most pain management in high-risk individuals.

Hydration — maintaining adequate fluid intake to produce at least 2 liters of urine per day (pale yellow urine) — reduces the concentration of potential kidney irritants in the tubules, decreases kidney stone risk, and reduces interstitial stress from concentrated urine. This is particularly relevant during exercise, summer heat, and any illness involving vomiting or diarrhea, when dehydration risk rises sharply.

Regular aerobic exercise — at least 150 minutes per week of moderate-intensity activity — produces consistent benefits for every major kidney disease risk factor: it lowers blood pressure, reduces body weight, improves insulin sensitivity, and reduces systemic inflammation. KDIGO includes physical activity as a standard recommendation in CKD management, not a soft suggestion.

Smoking cessation provides kidney-specific benefits beyond the well-known cardiovascular and pulmonary effects. Smoking causes direct endothelial dysfunction in the renal microvasculature and accelerates arteriosclerosis — mechanisms that are independent of blood pressure and contribute to faster eGFR decline in CKD patients who smoke. Quitting smoking is associated with measurably slower CKD progression in multiple observational studies.

Medications and Kidney Safety

Prevention is not only about what patients do — it also involves what medications they take and how they interact with kidney function. Several common medication safety considerations apply specifically to people at risk for kidney disease.

Every prescriber and pharmacist involved in a high-risk patient’s care should know the patient’s most recent eGFR. Many medications require dose adjustments at eGFR below 60, 45, or 30 — and some are contraindicated at advanced kidney function levels. This information is often not communicated between specialists, leaving high-risk patients exposed to nephrotoxic or accumulating drugs without the appropriate dose adjustment.

Intravenous contrast dye, used in CT scans and certain procedures, poses a contrast-induced AKI risk that is most significant in patients with CKD, diabetes, or dehydration. Pre-procedure intravenous hydration with normal saline, and avoidance of concurrent nephrotoxic agents on the day of contrast administration, substantially reduces this risk. Always inform the imaging team if you have diabetes or known kidney disease before a contrast procedure.

Aminoglycoside antibiotics (gentamicin, tobramycin) are directly nephrotoxic at standard doses and should be avoided in patients at kidney risk when alternative antibiotic classes are available. When they are clinically necessary, extended-interval dosing and close monitoring of renal function and drug levels is required. Gadolinium contrast for MRI is contraindicated at eGFR below 30 due to the risk of nephrogenic systemic fibrosis — a severe, progressive condition affecting the skin and internal organs.

Managing Conditions That Drive Kidney Risk

Several comorbid conditions accelerate kidney damage when not adequately treated, and their management is a direct component of kidney disease prevention.

Urinary tract infections should be treated promptly to prevent ascending infection reaching the kidneys. Repeated pyelonephritis (kidney infections) causes renal cortical scarring — reflux nephropathy — that reduces functional kidney mass permanently. Patients with frequent UTIs, particularly women and those with structural urinary tract abnormalities, should discuss a urology evaluation to identify preventable causes.

Kidney stones cause tubular obstruction and injury with each episode and, if not managed, recur at a 50 percent rate within 10 years. Prevention depends on the stone type: calcium oxalate stones (most common) are prevented by high fluid intake, moderate dietary oxalate, and avoiding calcium restriction (which paradoxically worsens oxalate absorption). Uric acid stones are prevented by fluid intake and urinary alkalinization with potassium citrate. For any patient with a documented kidney stone, a 24-hour urine collection assessment and metabolic evaluation by a nephrologist or urologist provides the most effective individualized prevention strategy.

Sleep apnea is associated with CKD progression through mechanisms including intermittent hypoxia, elevated sympathetic nervous system activation, and nocturnal blood pressure surges. Treatment of sleep apnea with CPAP has been associated with improved blood pressure control, and emerging data suggest a kidney-protective effect in patients with OSA and CKD.

If You Already Have Early CKD — Secondary Prevention

For patients who have already been diagnosed with Stage G1 or G2 CKD — early stages where eGFR is above 60 but damage markers (typically albuminuria) are present — the prevention framework shifts from avoiding CKD to preventing its progression. The evidence base for secondary prevention at early CKD is among the strongest in nephrology.

If albuminuria is present, RAAS blockade with an ACE inhibitor or ARB is the foundation of treatment — reducing intraglomerular pressure, lowering proteinuria, and directly slowing the structural injury cycle. For patients with type 2 diabetes and CKD, adding an SGLT2 inhibitor provides a second, additive mechanism of kidney protection. Blood pressure control below 130/80 becomes the explicit target rather than a general goal. Metabolic acidosis (serum bicarbonate below 22 mEq/L) should be treated with oral sodium bicarbonate. eGFR and uACR monitoring every six to twelve months tracks whether the intervention is working — a rising uACR despite treatment is the signal to intensify management, not to wait. The trajectory of what happens from Stage G1 through to advanced CKD — and what intervention at each stage achieves — is explained in our guide to chronic kidney disease stages explained, and the specific evidence for slowing progression at each stage is covered in our article on slowing kidney disease progression.

Nephrology referral is recommended when eGFR falls below 45, when uACR exceeds 300 mg/g, when the rate of eGFR decline exceeds 5 ml/min/year, or when the cause of kidney disease is uncertain and biopsy might change management. Earlier referral is better — a nephrologist’s involvement at Stage G3 rather than G4 allows time for unhurried preparation of kidney replacement therapy options if progression continues. The full monitoring checklist that guides annual CKD care is outlined in the annual kidney health checklist, and the early-stage monitoring rationale is explained in our companion article on early chronic kidney disease: why monitoring matters.

APOL1 and Genetic Risk in Black Americans

For Black Americans — who face a 3.7-fold higher risk of kidney failure compared to white Americans — the APOL1 gene variants G1 and G2 explain a substantial proportion of the excess risk. Individuals who carry two APOL1 risk alleles (approximately 13 percent of Black Americans) face dramatically elevated risk for focal segmental glomerulosclerosis (FSGS) and hypertensive ESRD — conditions that can progress rapidly even when blood pressure appears adequately controlled.

APOL1 genotyping is available but not yet standard of care outside research settings. However, awareness of the elevated population risk should inform clinical decisions: Black Americans with hypertension or family history of kidney disease should be screened earlier, monitored more frequently, and have their blood pressure controlled to the most aggressive achievable target. An investigational therapy targeting the APOL1 protein directly — inaxaplin — has received FDA Breakthrough Therapy designation and is in Phase 3 trials. If approved, it would be the first kidney-protective therapy specifically addressing the APOL1-driven pathway. Until then, the actionable message is heightened vigilance, aggressive BP control, and regular nephrology involvement for high-risk individuals.

Taking Action — What to Do at Your Next Visit

Kidney disease prevention translates into concrete actions at medical appointments that most patients in high-risk groups are not currently taking. The most impactful questions to raise at a primary care or specialist visit include: Has my eGFR been checked in the past year? Has my urine albumin (uACR) been checked? Based on my risk factors, should I be screened for CKD annually? Is there a medication that would specifically protect my kidneys — an ACE inhibitor, ARB, or SGLT2 inhibitor? What is my blood pressure target, and am I meeting it consistently? Are there any medications I take regularly that could harm my kidneys?

These questions are straightforward but consistently under-asked in routine care — largely because patients do not know to ask them. Raising them moves the conversation from reactive symptom management to proactive kidney protection. The three external resources most useful for patients in high-risk groups are the NIDDK’s CKD prevention resource, the National Kidney Foundation’s kidney disease prevention guide, and the American Diabetes Association’s guidance on diabetic kidney disease. Each provides regularly updated, patient-facing information that complements what a care team provides at appointments.

Kidney disease prevention is not a single step or a one-time conversation — it is a consistent, sustained engagement with the modifiable factors that determine kidney outcomes over a lifetime. The patients who do best are those who understand their risk group, get the right tests at the right frequency, control the conditions that drive kidney damage, and engage their care team proactively rather than reactively. The window for prevention is open from the first recognized risk factor; it closes gradually as kidney function declines and is never fully open again once kidney failure is reached.

Sources: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); KDIGO 2024 CKD Evaluation and Management Guidelines; National Kidney Foundation; American Diabetes Association Standards of Care; US Renal Data System (USRDS) 2023; UK Prospective Diabetes Study (UKPDS).